Phosphoproteomic profiling of arsenite-treated human small airway epithelial cells

Oncology Reports

Volumn 23, Issue 2, 2010, Pages 405-412

  Wen, Gengyun ^a   Hong, M ^a,b   Calaf, G M ^a,c   Roy, D ^d   Partridge, M A ^a   Li, B ^a,e   Hei, T K ^a  

^a NewYork Presbyterian Hospital   (United States)

^b SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^c UNIVERSIDAD DE TARAPACÁ   (Chile)

^d CITY UNIVERSITY OF NEW YORK   (United States)

^e SOOCHOW UNIVERSITY   (China)

Author keywords

Arsenite; Mitogen activated protein kinases; Phosphoproteomic profiling; Phosphor receptor tyrosine kinases

Indexed keywords

ARSENIC TRIOXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FLT3 LIGAND; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 10; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHO RECEPTOR TYROSINE KINASE; PHOSPHOPROTEIN; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; PLATING MEDIUM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; RESPIRATORY EPITHELIUM; SIGNAL TRANSDUCTION;

ARSENITES; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; ENZYME INHIBITORS; EPITHELIAL CELLS; HUMANS; METABOLOME; PHOSPHOPROTEINS; PROTEOME; PROTEOMICS; RECEPTOR PROTEIN-TYROSINE KINASES; RESPIRATORY MUCOSA; TERATOGENS;

EID: 76649102773     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000649     Document Type: Article

References (45)

1. Bode AM and Dong Z: The paradox of arsenite: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 42: 5-24, 2002.
2. Basu A, Mahata J, Gupta S and Giri AK: Genetic toxicology of a paradoxical human carcinogen, arsenite: a review. Mutat Res 488: 171-194, 2001.
3. Morales KH, Ryan L, Kuo TL, Wu MM and Chen CJ: Risk of internal cancers from arsenite in the drinking water. Environ Health Perspect 108: 655-661, 2000.
4. Aposhian HV: Arsenite toxicology: does methylation of arsenite species have an evolutionary significance? Met Ions Biol Med 4: 399-401, 1996.
5. Marshall G, Ferreccio C, Yuan Y, Bates MN, Steimaus C, Liaw J and Smith AH: Fifty-year study of lung and bladder cancer mortality in Chile related to arsenite in drinking water. J Natl Cancer Inst 99: 920-928, 2007.
6. Chowdhury TR, Basu GK, Mandal BK, et al: Arsenite poisoning in the Ganges delta. Nature 401: 545-546, 1999.
7. National Research Council: Arsenite in Drinking Water. National Academy Press, Washington, DC, 2000.
8. Tseng WP, Chu HM, How SW, Fong JM, Lin CS and Yeh S: Prevalence of skin cancer in an endemic area of Chronic arseniteism in Taiwan. J Natl Cancer Inst 40: 453-463, 1968.
9. Cebrián ME, Albores A, Aguilar M and Blakely E: Chronic arsenite poisoning in the north of Mexico. Hum Toxicol 2: 121-133, 1983.
10. IARC: Some drinking-water disinfectants and contaminants, including arsenic. Working group on the Evaluation of Carcinogenic Risks to Humans. IARC Monogr Eval Carcinog Risks Hum 84: 1-477, 2004.
11. Lee TC, Oshimura M and Barrett JC: Comparison of arsenite-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis 6: 1421-1426, 1985.
12. Hei TK, Liu SX and Waldren C: Mutagenicity of arsenite in mammalian cells: Role of reactive oxygen species. Proc Natl Acad Sci USA 95: 8103-8107, 1998.
13. Gurr JR, Lin YC, Ho IC, Jan KY and Lee TC: Induction of chromatid breaks and tetraploidy in Chinese hamster ovary cells by treatment with sodium arsenite during the G2 phase. Mutat Res 319: 135-142, 1993.
14. Wang TS and Huang H: Active oxygen species are involved in the induction of micronuclei by arsenite in XRS-5 cells. Mutagenesis 9: 253-257, 1994.
15. Chen CJ and Wang CJ: Ecological correlation between arsenite level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 5: 5470-5474, 1990.
16. Liu SX, Athar M, Lippai I, Waldren C and Hei TK: Induction of oxyradicals by arsenite: Implication for mechanism of genotoxicity. Proc Natl Acad Sci USA 98: 1643-1648, 2001.
17. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K and Karin M: The tumor promoter arsenite simulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15: 6269-6279, 1996.
18. Samet JM, Graves LM, Quay J, et al: Activation of MAPKs in human bronchial epithelial cells exposed to metals. Am J Physiol 275: L551-L558, 1998.
19. Reichard JF, Schnekenburger M and Puga A: Long term low-dose arsenite exposure induces loss of DNA methylation. Biochem Biophysic Res Commun 352: 188-192, 2007.
20. Wu W, Graves LM, Jaspers I, Devlin RB, Reed W and Samet JM: Activation of the EGF receptor signaling: pathway in human airway epithelial cells exposed to metals. Am J Physiol 277: L924-L931, 1999.
21. Wilbourne J, Haroun L, Heseltine E, Kaldor J, Partensky D and Vainio V: Response of experimental animals to human carcinogens: an analysis based upon the IARC monographs programme. Carcinogenesis 7: 1853-1863, 1986.
22. Lau AT, He QY and Chiu JF: Proteomic technology and its biomedical applications. Acta Biochim Biophys Sin 35: 965-975, 2003.
23. Jungblut PR, Zimny-Arndt U, Zeindl-Eberhart E, et al: Proteomics in human disease: cancer, heart and infectious diseases. Electrophoresis 20: 2100-2110, 1999.
24. Mumby M and Brekken D: Phosphoproteomics: new insights into cellular signaling. Genome Biol 6: 230, 2005.
25. Gembitsky DS, Lawlor K, Jacovina A, Yaneva M and Tempst P: A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation. Mol Cell Proteomics 3: 1102-1118, 2004.
26. Piao CQ, Liu L, Zhao YL, Balajee AS, Suzuki M and Hei TK: Immortalization of human small airway epithelial cells by ectopic expression of telomerase. Carcinogenesis 26: 725-731, 2005.
27. Samet JM, Silbajoris R, Wu W and Graves LM: Tyrosine phosphatases as targets in metal-induced signaling in human airway epithelial cells. Am J Respir Cell Mol Biol 21: 357-364, 1999.
28. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
29. Hober S and Uhlén M: Human protein atlas and the use of microarray technologies. Curr Opin Biotechnol 19: 30-35, 2008.
30. Roy D, Calaf G and Hei TK: Profiling of differentially expressed genes induced by high linear energy transfer radiation in breast epithelial cells. Mol Carcinogen 31: 192-203, 2001.
31. Lei T, He QY, Cai, Z, et al: Proteomic analysis of chromium cytotoxicity in cultured rat lung epithelial cells. Proteomics 8: 2420-2429, 2008.
32. Wen G, Calaf GM, Partridge MA, et al: Neoplastic transformation of human small airway epithelial cells induced by arsenite. Mol Med 14: 2-10, 2008.
33. Tanaka-Kagawa T, Hanioka N, Yoshida H, Jinno H and Ando M: Arsenite and arsenate activate extracellular signal-regulated kinases 1/2 by an epidermal growth factor receptor-mediated pathway in normal human keratinocytes. Br J Dermatol 149: 1116-1127, 2003.
34. Ivanov VN and Hei TK: Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene 24: 616-626, 2005.
35. Díaz-Villaseñor A, Burns AL, Hiriart M, Cebrián ME and Ostrosky-Wegman P: Arsenite-induced alteration in the expression of genes related to type 2 diabetes mellitus. Toxicol Appl Pharmacol 225: 123-133, 2007.
36. Paul DS, Harmon AW, Devesa V, Thomas DJ and Styblo M: Molecular mechanisms of the diabetogenic effects of arsenite: inhibition of insulin signaling by arsenite and methylarsonous acid. Environ Health Perspect 115: 734-742, 2007.
37. Shen J, Liu J, Xie Y, Diwan BA and Waalkes MP: Fetal onset of aberrant gene expression relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenite exposure. Toxicol Sci 95: 313-320, 2007.
38. Patterson TJ and Rice RH: Arsenite and insulin exhibit opposing effects on epidermal growth factor receptor and keratinocyte proliferative potential. Toxicol Appl Pharmacol 221: 119-128, 2007.
39. Wetzler M, Brady MT, Tracy E, et al: Arsenite trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res 12: 6817-6825, 2006.
40. Amadori S, Fenaux P, Ludwig H, O'Dwyer M and Sanz M: Use of arsenite trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 21: 403-411, 2005.
41. Takahashi S, Harigae H, Yokoyama H, et al: Synergistic effect of arsenite trioxide and Flt3 inhibition on cells with Flt3 internal tandem duplication. Int J Hematol 84: 256-261, 2006.
42. Cheng Y, Chang LW and Tsou TC: Mitogen-activated protein kinases mediate arsenite-induced down-regulation of surviving in human lung adenocarcinoma cells. Arch Toxicol 80: 310-318, 2006.
43. Hossain K, Akhand AA and Kawamto Y: Caspase activation is accelerated by the inhibition of arsenite-induced, membrane-rafts-dependent AKT activation. Free Radic Biol Med 34: 598-606, 2003.
44. Souza K, Maddock DA, Zhang Q, Chen J, Chiu C, Mehta S and Wan Y: Arsenite activation of P13K/AKT cell survival pathway is mediated by p38 in cultured human keratinocytes. Mol Med 7: 767-772, 2001.
45. Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J and Chen G: p38 isoforms have opposite effects on AP-1 dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem 278: 4831-4839, 2003.